Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. (Source: World Pharma News)
Source: World Pharma News - January 20, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Jan 6, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced appointment of Yong Fan, MD, as Senior Vice Pr... Biopharmaceuticals, Oncology, Personnel CARsgen Therapeutics, T cell, CAR-T, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 6, 2020 Category: Pharmaceuticals Source Type: news
Surgical Resection vs RFA for Very Early-stage HCC Surgical Resection vs RFA for Very Early-stage HCC
This analysis compared surgical resection to radiofrequency ablation as the first-line treatment for very early-stage hepatocellular carcinoma. Which option produced best recurrence-free survival?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
No Survival Difference Between Re-Resection, Percutaneous RFA in Recurrent HCC No Survival Difference Between Re-Resection, Percutaneous RFA in Recurrent HCC
In patients with early-stage recurrent hepatocellular carcinoma (HCC), long-term survival does not differ between repeat hepatectomy and percutaneous radiofrequency ablation (RFA), a randomized trial in China suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 10, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Improved Survival Seen in Hepatoma Patients After HCV Cure Improved Survival Seen in Hepatoma Patients After HCV Cure
Cure of hepatitis C virus (HCV) infection with direct-acting antivirals is associated with increased survival in patients with HCV-related hepatocellular carcinoma (HCC), researchers report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 29, 2019 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
